Navigation Links
Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
Date:2/13/2008

SOUTH SAN FRANCISCO, Calif., Feb. 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it completed enrollment of patients in the maximum tolerated dose (MTD) cohort expansion segment of its Phase 1/2a trial of RAV12, an anti-cancer monoclonal antibody. The trial enrolled patients with cancers that express the RAAG12 antigen, particularly those of gastrointestinal origin. All patients in the trial have undergone radiographic re-evaluation to assess their response to treatment. Based on this assessment, two patients remain on study drug beyond the original treatment period. A total of four patients received extended therapy in both the original cohort and the expanded cohort of this trial.

"We continue to be pleased with our advances with RAV12 and the indications of its potential therapeutic value." said George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies.

RAAG12 is a glycotope (sugar structure) that is widely found on the surface of tumor cells of many kinds of cancer, particularly cancers of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody drug candidate, targets the RAAG12 antigen.

An analysis of data from this trial is expected in the second or third quarter of this year. The analysis will produce an evaluation of safety, definitive pharmacokinetics, evaluation of immunogenicity, and estimates of efficacy in a refractory patient population.

The appropriate dose and schedule of RAV12 previously was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved side effect profile for the antibody. The recently concluded MTD Cohort Expansion segment involved 20 additional patients. '/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Dynatronics Corporation (NASDAQ: DYNT ) today ... to the Company,s Board of Directors effective March 23, 2015, ... 2014 of board member Joseph Barton .  ... Board of Directors represents an important step forward for the ... of Dynatronics.  "Rich is a proven leader and is well-known ...
(Date:3/27/2015)... TEMPLE, Texas , March 27, 2015 The ... relocate in April to a 5,000-square-foot building at 1802 South ... a geographic area designated by the City of ... Baylor Scott & White and the Central Texas Veterans Health ... office and laboratory space to early stage biotechnology and life ...
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... Dec. 16, 2010 WaferGen Biosystems, Inc. (OTC Bulletin ... state-of-the-art genomic analysis systems, and the Integrated BioBank of ... strategic relationship that will expand the use of the ... personalized medicine.   The agreement includes: ...
... FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 ... on the development and commercialization of first-in-class targeted ... Paris: FR0005175080), a bio-pharmaceutical company specialized in the ... and treatment of patients in a Phase 1b ...
Cached Medicine Technology:WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer 2Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer 3Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer 4Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer 5
(Date:3/28/2015)... Coffee could not only perk you up in the morning ... have found. , They found that those who drank coffee ... fight gum disease. Does coffee, then, help fight gum disease? ... Goldman School of Dental Medicine explored in a study ... of Periodontology. , “This is the first long-term study of ...
(Date:3/28/2015)... 2015 Thousands of transvaginal mesh ... C.R. Bard, Inc. continue to move forward in ... Southern District of West Virginia, where Bernstein Liebhard ... Plaintiffs’ Steering Committee. According to an Order ... defendants named in those lawsuits leave to amend ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Centurion Service Group ... auction on Thursday, April 2 at their Las Vegas warehouse, ... NV 89081. The sale, which consists of equipment from hospitals ... promptly at 9 a.m. PDT. , Buyers will find ... surgery equipment. “We are a one-stop-shop,” said Erik Tivin, CEO ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... option for patients with Type V AC joint injuries, ... The study, presented today at the American Orthopaedic Society ... military personnel returned to duty faster when surgery was ... 24 patients, with 7 receiving surgical treatment and 17 ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... You,re late for work, your toddler,spilled jam on your suit ... with,the rising anger? Whether you brush it off and move ... affects not only yourself, but also,your spouse, your children and ... to stay calm, situations always arise that push,our buttons. While ...
... Store and Prepare Fruits,and Vegetables, Making it Easier to ... time just around the corner, the Produce for Better ... and combat the,national childhood obesity epidemic by focusing on ... help Moms instill good eating habits,and fight unhealthy food ...
... The Scale-Aire, a high-speed dental air unit designed for ... , ... Louisville, KY ... http://www.dreveterinary.com/index.php [veterinary equipment] company, is distributing the ...
... Service Reach, Green IT Strategy and Educational Market Momentum ... ... Communications, a leading regional provider of hosted telephony and managed Voice-over-IP ... latest two deployments of its Voicepath solution for the University of ...
... PHILADELPHIA, Aug. 20 Peer-reviewed safety ... Intramuscular Stimulation (eToims(R)),successfully applied to patients ... the August/September issue of Electromyography and,Clinical ... of,Pennsylvania associated physicians Jennifer Chu, M.D. ...
... Development (USAID) is expediting the shipment of nearly,24,000 metric tons ... in need,of assistance in the Horn of Africa. The shipment ... oil, 6,320 MT of corn soy blend,and 1,400 MT of ... implementing to alleviate impacts of the world food crisis in ...
Cached Medicine News:Health News:Taming Your Temper: Learning to Turn Down the Heat 2Health News:Fruits & Veggies - More Matters Helps Moms Instill Healthy Eating Habits 2Health News:Fruits & Veggies - More Matters Helps Moms Instill Healthy Eating Habits 3Health News:DRE Veterinary Distributes All-In-One Veterinary Dental Cart 2Health News:DRE Veterinary Distributes All-In-One Veterinary Dental Cart 3Health News:University of Mobile Taps Callis Communications for Hosted VoIP and Wireless Internet 2Health News:University of Mobile Taps Callis Communications for Hosted VoIP and Wireless Internet 3Health News:Positive Findings Published on Emergent Technology for Treating Chronic Pain 2Health News:USAID Expedites Emergency Food Aid to Horn of Africa 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: